Methenamine Hippurate Pfleger
Urinary antiseptic for prevention of recurrent urinary tract infections
Quick Facts About Methenamine Hippurate Pfleger
Key Takeaways
- Not an antibiotic: Methenamine hippurate is a urinary antiseptic that does not contribute to antimicrobial resistance, making it ideal for long-term prophylaxis
- Requires acidic urine: The medication only works when urine pH is below 5.5 – dietary measures or vitamin C supplementation may be recommended
- Proven efficacy: Cochrane reviews show methenamine hippurate significantly reduces recurrent UTIs in patients without urinary tract abnormalities
- Not for acute infections: This medication prevents UTIs but does not treat active infections – antibiotics are needed for acute UTI
- Key drug interactions: Avoid combining with sulfonamides and alkalinizing agents that raise urine pH
What Is Methenamine Hippurate Pfleger and What Is It Used For?
Methenamine hippurate Pfleger is a urinary antiseptic prescribed for the long-term prevention (prophylaxis) of recurrent urinary tract infections (UTIs). It works as a prodrug, releasing formaldehyde in acidic urine to kill bacteria. It is not an antibiotic and does not treat acute infections.
Methenamine hippurate is one of the oldest urinary antiseptics in clinical use, with a history dating back over a century. The medication belongs to the pharmacological class of urinary antiseptics (ATC code J01XX05) and functions through a unique mechanism that sets it apart from conventional antibiotics. When the drug reaches the bladder, where the urine is sufficiently acidic (pH below 5.5), methenamine undergoes hydrolysis to release formaldehyde. This formaldehyde acts as a potent, non-specific bactericidal agent that denatures bacterial proteins and nucleic acids.
The hippuric acid component of the compound serves a dual purpose. First, it contributes to the acidification of urine, helping to maintain the low pH environment necessary for formaldehyde release. Second, hippuric acid itself possesses mild bacteriostatic properties that complement the action of formaldehyde. This synergistic effect makes methenamine hippurate particularly effective as a prophylactic agent.
One of the most significant advantages of methenamine hippurate over conventional antibiotics is the absence of bacterial resistance development. Because formaldehyde works through a non-specific mechanism – essentially denaturing all proteins it contacts – bacteria cannot develop targeted resistance mechanisms as they do with antibiotics. This property makes methenamine hippurate especially valuable in an era of increasing antimicrobial resistance, as highlighted by the World Health Organization (WHO) and the European Association of Urology (EAU) guidelines.
The primary clinical indication for methenamine hippurate Pfleger is the prophylaxis of recurrent uncomplicated urinary tract infections, particularly in women who experience frequent episodes. It may also be used in patients with indwelling urinary catheters or those undergoing urinary tract instrumentation, although evidence in these populations is more limited. The European Association of Urology (EAU) 2024 guidelines on urological infections recognize methenamine hippurate as a non-antibiotic alternative for UTI prophylaxis.
Methenamine hippurate Pfleger is strictly a preventive medication. It is not effective for treating acute urinary tract infections. If you develop symptoms of an active UTI (burning during urination, frequent urge to urinate, cloudy or bloody urine), contact your healthcare provider for appropriate antibiotic treatment.
What Should You Know Before Taking Methenamine Hippurate Pfleger?
Before starting methenamine hippurate Pfleger, discuss your complete medical history with your healthcare provider, especially any kidney or liver problems, dehydration, or current medications. This drug is contraindicated in severe renal impairment, hepatic insufficiency, and severe dehydration.
Contraindications
Methenamine hippurate Pfleger must not be used in certain clinical situations. Understanding these contraindications is essential for safe use of the medication. The following conditions represent absolute contraindications:
- Severe renal impairment: Patients with significantly reduced kidney function (GFR below 30 mL/min) should not take methenamine hippurate because the kidneys cannot adequately concentrate the drug in the urine, and there is a risk of formaldehyde accumulation in the systemic circulation
- Hepatic insufficiency: Severe liver disease impairs the metabolism of methenamine and may increase the risk of toxicity. Patients with hepatic impairment should avoid this medication
- Severe dehydration: Dehydrated patients produce concentrated, low-volume urine that may lead to excessive formaldehyde concentration in the bladder, potentially causing chemical irritation of the bladder mucosa
- Hypersensitivity: Known allergy to methenamine, hippuric acid, or any excipient in the formulation
- Gout: Hippuric acid may interfere with uric acid excretion, potentially worsening gout symptoms in susceptible patients
Warnings and Precautions
Several important warnings and precautions apply to methenamine hippurate therapy. Patients should be aware of these considerations to use the medication safely and effectively:
- Urine pH monitoring: Effectiveness depends on maintaining urine pH below 5.5. Patients may need to monitor urine pH periodically and adjust diet or supplements accordingly. High-protein foods, cranberry juice, and vitamin C (ascorbic acid) can help acidify urine
- Adequate fluid intake: While adequate hydration is important, excessive fluid intake can dilute urine formaldehyde concentration and reduce efficacy. A moderate fluid intake of approximately 1.5–2 liters per day is generally recommended
- Renal function monitoring: Regular monitoring of kidney function is advisable during long-term therapy, particularly in elderly patients or those with borderline renal function
- Bladder irritation: Prolonged use at high doses may cause chemical irritation of the bladder lining (chemical cystitis). Report symptoms such as painful urination, bladder discomfort, or hematuria (blood in urine) to your healthcare provider
- Urinalysis interference: Formaldehyde in urine can interfere with certain laboratory tests, including urinary catecholamine assays and some glucose tests. Inform laboratory staff that you are taking this medication
Pregnancy and Breastfeeding
The use of methenamine hippurate during pregnancy and breastfeeding requires careful consideration by a healthcare provider. While animal reproductive studies have not demonstrated clear evidence of fetal harm, human data is limited. Methenamine does cross the placenta, and formaldehyde is a known teratogen at high concentrations in animal studies.
Current guidelines from the European Medicines Agency (EMA) suggest that methenamine hippurate should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus. Many clinicians prefer to use this agent during the second and third trimesters if prophylaxis is needed, avoiding first-trimester exposure when possible.
Methenamine is excreted in breast milk in small quantities. The clinical significance of this excretion for the nursing infant is not well established, but most expert sources consider the risk to be low. Nonetheless, breastfeeding mothers should consult their healthcare provider before taking this medication.
If you are pregnant, planning to become pregnant, or breastfeeding, always consult your doctor before starting or continuing methenamine hippurate Pfleger. Do not start or stop this medication without medical advice.
How Does Methenamine Hippurate Pfleger Interact with Other Drugs?
Methenamine hippurate has several clinically significant drug interactions. The most important is with sulfonamide antibiotics, which can form insoluble precipitates with formaldehyde in the urinary tract. Urinary alkalinizers also reduce its effectiveness by raising urine pH above the threshold needed for drug activation.
Understanding drug interactions is critical for the safe and effective use of methenamine hippurate. Because the drug's mechanism of action depends on urinary pH, any medication that alters urine acidity can impact its efficacy. Additionally, the release of formaldehyde creates specific interaction risks with certain drug classes.
Major Interactions
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Sulfonamides (sulfamethoxazole, sulfadiazine) | Formaldehyde reacts with sulfonamides to form insoluble precipitates in the urinary tract | Risk of crystalluria, urinary obstruction, and renal damage. Combination is contraindicated |
| Sodium bicarbonate | Alkalinizes urine, raising pH above 5.5 and preventing formaldehyde release | Completely negates the therapeutic effect of methenamine hippurate |
| Potassium citrate / Sodium citrate | Potent urinary alkalinizers that elevate urine pH significantly | Renders methenamine hippurate ineffective. Avoid concurrent use |
| Acetazolamide | Carbonic anhydrase inhibitor that alkalinizes urine as a side effect | Raises urine pH, substantially reducing methenamine efficacy |
Minor Interactions and Considerations
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Antacids (aluminum/magnesium hydroxide) | May alkalinize urine if used in large or frequent doses | Monitor urine pH if regular antacid use is required |
| Thiazide diuretics | May alter urine pH and electrolyte balance | Monitor urine pH; usually clinically manageable |
| Ascorbic acid (Vitamin C) | Acidifies urine, potentially enhancing methenamine activity | Beneficial interaction; often co-prescribed to maintain acidic urine |
| Cranberry products | May modestly acidify urine and possess independent antibacterial properties | Generally considered complementary; no adverse interaction known |
Patients should always inform their healthcare provider and pharmacist of all medications they are currently taking, including over-the-counter drugs, supplements, and herbal products. This is particularly important for methenamine hippurate because even seemingly benign products such as antacids and bicarbonate-containing supplements can compromise the drug's efficacy.
What Is the Correct Dosage of Methenamine Hippurate Pfleger?
The standard adult dose of methenamine hippurate Pfleger is 1 g (one tablet) taken twice daily, usually morning and evening. The tablets should be swallowed whole with water. Dosage adjustments may be necessary based on renal function, and the medication is generally not recommended for children under 6 years of age.
Adults
Standard Adult Dosage
Dose: 1 g (one tablet) twice daily
Timing: Morning and evening, preferably at the same times each day
Administration: Swallow the tablet whole with a full glass of water. May be taken with or without food, although taking it with food may reduce gastrointestinal side effects
Duration: As directed by your healthcare provider, often for several months to years for chronic UTI prophylaxis
The standard adult dosage reflects the pharmacokinetic properties of methenamine hippurate. After oral administration, the drug is rapidly absorbed from the gastrointestinal tract. Peak plasma levels are achieved within 1–2 hours, and the drug is primarily excreted unchanged by the kidneys. The twice-daily dosing regimen ensures sustained urinary formaldehyde concentrations throughout the day, providing continuous antibacterial prophylaxis.
For optimal efficacy, patients are often advised to consume an acidifying diet alongside the medication. Foods that help lower urine pH include proteins (meat, fish, eggs), whole grains, cranberries, and plums. Some physicians recommend concurrent supplementation with ascorbic acid (vitamin C) at doses of 500–1000 mg daily to further acidify the urine.
Children
Pediatric Dosage (Children 6–12 years)
Dose: 500 mg (half a tablet) twice daily
Note: Use in children under 6 years is generally not recommended due to limited safety data
Administration: If the tablet must be split, ensure accurate halving. Consult a pharmacist for guidance
Pediatric use of methenamine hippurate should be supervised by a physician experienced in pediatric infectious diseases. The decision to use this medication in children must weigh the potential benefits of UTI prophylaxis against the limited pediatric safety data. In children over 12 years of age, the adult dosage of 1 g twice daily is generally appropriate.
Elderly
Elderly Patients
Dose: 1 g twice daily (same as standard adult dose)
Considerations: Renal function should be assessed before initiating therapy and monitored periodically. Dose adjustment may be necessary if renal function declines
Fluid intake: Ensure adequate but not excessive hydration (approximately 1.5–2 liters per day)
Elderly patients are among the most common users of methenamine hippurate, given the increased incidence of recurrent UTIs in this population. Age-related decline in renal function must be considered, as impaired kidney function can reduce drug efficacy and increase the risk of adverse effects. Regular renal function monitoring through serum creatinine and estimated GFR is recommended.
Missed Dose
If you miss a dose of methenamine hippurate Pfleger, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for the missed one, as this can increase the risk of bladder irritation and other side effects.
Consistency in taking the medication at the prescribed times is important for maintaining adequate urinary formaldehyde levels. Setting regular reminders or incorporating the medication into your daily routine (such as taking it with breakfast and dinner) can help ensure adherence.
Overdose
Overdose with methenamine hippurate is uncommon but can result in gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea. In more severe cases, chemical irritation of the bladder (chemical cystitis) may occur, presenting as painful urination, urinary frequency, and hematuria (blood in urine).
If you suspect an overdose, contact your local poison control center or seek immediate medical attention. Treatment is primarily supportive, focusing on adequate hydration and monitoring of renal function. There is no specific antidote for methenamine hippurate overdose.
If you have taken more methenamine hippurate than prescribed, or if a child has accidentally ingested this medication, contact your local poison control center or emergency services immediately. Do not wait for symptoms to appear.
What Are the Side Effects of Methenamine Hippurate Pfleger?
Methenamine hippurate is generally well tolerated. The most common side effects are gastrointestinal disturbances such as nausea and stomach upset. Bladder irritation (dysuria) can occur, particularly at higher doses or when urine pH is not adequately maintained. Serious side effects are rare.
Like all medicines, methenamine hippurate Pfleger can cause side effects, although not everybody gets them. Most side effects are mild and transient, resolving either spontaneously or with dosage adjustment. The following frequency classification is based on available clinical data and pharmacovigilance reports:
Common
- Nausea
- Stomach upset or abdominal discomfort
- Loss of appetite
- Dysuria (painful or difficult urination)
Uncommon
- Vomiting
- Diarrhea
- Abdominal cramps
- Skin rash
- Bladder irritation (chemical cystitis)
Rare
- Hematuria (blood in urine)
- Elevated liver enzymes
- Generalized pruritus (itching)
- Allergic reactions (urticaria, angioedema)
- Tinnitus (ringing in the ears)
Most gastrointestinal side effects can be minimized by taking methenamine hippurate with food. If nausea persists, your doctor may recommend a temporary dose reduction or adjustments to your meal timing. Bladder irritation symptoms typically indicate excessive formaldehyde concentration in the urine and may improve with slightly increased fluid intake or dose adjustment.
Long-term use of methenamine hippurate at standard doses has been studied extensively and is generally considered safe. A landmark Cochrane systematic review found no significant increase in serious adverse events compared to placebo in prophylactic studies lasting up to 12 months. However, periodic medical review is advisable for patients on extended therapy.
Seek medical attention if you experience any of the following: persistent blood in urine, signs of allergic reaction (rash, swelling of face or throat, difficulty breathing), severe abdominal pain, or yellowing of the skin or eyes (jaundice). These symptoms may indicate a serious adverse reaction requiring immediate evaluation.
How Should You Store Methenamine Hippurate Pfleger?
Store methenamine hippurate Pfleger tablets at room temperature (below 25°C / 77°F) in the original packaging. Keep away from moisture and direct light. Keep out of sight and reach of children.
Proper storage of methenamine hippurate Pfleger ensures that the medication remains effective throughout its shelf life. Follow these storage guidelines carefully:
- Temperature: Store at room temperature, ideally between 15°C and 25°C (59°F to 77°F). Do not refrigerate or freeze
- Moisture protection: Keep tablets in their original packaging or container with the lid tightly closed. Moisture can degrade the medication, reducing its potency
- Light protection: Store away from direct sunlight and strong artificial light
- Child safety: Keep out of sight and reach of children. Consider using child-resistant containers
- Expiration: Do not use the tablets after the expiration date printed on the packaging. Expired medication should be returned to a pharmacy for proper disposal
Do not flush medications down the toilet or discard them in household waste unless specifically instructed to do so. Consult your pharmacist about proper disposal methods for unused or expired medicines. Many communities have medication take-back programs that ensure safe disposal of pharmaceutical products.
What Does Methenamine Hippurate Pfleger Contain?
Each tablet of Methenamine Hippurate Pfleger contains 1 g of methenamine hippurate as the active ingredient. The medication is a salt formed from methenamine (hexamethylenetetramine) and hippuric acid.
Active Ingredient
The active substance is methenamine hippurate (also known as hexamine hippurate), present at a strength of 1 g per tablet. Methenamine hippurate is a chemical compound consisting of two components:
- Methenamine (hexamethylenetetramine): The prodrug component that releases formaldehyde in acidic conditions. Methenamine itself is pharmacologically inactive and must be hydrolyzed to its active metabolite in acidic urine
- Hippuric acid: A naturally occurring organic acid found in urine. The hippurate salt form serves to acidify the urine, facilitating the conversion of methenamine to formaldehyde. Hippuric acid also has mild bacteriostatic properties of its own
Excipients
In addition to the active ingredient, the tablet formulation contains various excipients (inactive ingredients) that serve as binders, fillers, and coating agents. Common excipients found in methenamine hippurate tablet formulations include:
- Magnesium stearate (lubricant)
- Povidone (binder)
- Microcrystalline cellulose (filler)
- Colloidal silicon dioxide (glidant)
Patients with known hypersensitivity to any excipient should review the full list of ingredients with their pharmacist before starting the medication. The complete excipient list can be found on the product label or the patient information leaflet supplied with the medication.
Frequently Asked Questions
Methenamine hippurate Pfleger is used for the long-term prevention (prophylaxis) of recurrent urinary tract infections (UTIs). It is a urinary antiseptic, not an antibiotic, that works by releasing formaldehyde in acidic urine to kill bacteria in the urinary tract. It is particularly useful for patients who experience frequent UTIs and want to reduce their reliance on antibiotics for prevention.
Methenamine hippurate is a prodrug. When it reaches the acidic environment of the urine (pH below 5.5), it is hydrolyzed into formaldehyde and hippuric acid. Formaldehyde has broad-spectrum bactericidal properties that kill most bacteria causing urinary tract infections by denaturing their proteins. The hippuric acid component helps maintain the acidic urine environment necessary for this process.
Methenamine hippurate should generally be avoided during pregnancy unless your healthcare provider determines that the potential benefit outweighs the risk. While animal studies have not shown clear harm, there is limited human data. If you are pregnant or planning to become pregnant, always consult your doctor before starting or continuing this medication.
Methenamine requires a urine pH below 5.5 to undergo hydrolysis and release formaldehyde, which is the active bactericidal component. In alkaline or neutral urine, this chemical reaction does not occur efficiently, and the drug remains inactive. To help maintain acidic urine, your doctor may recommend consuming acidifying foods (cranberries, protein-rich foods), taking vitamin C supplements, or avoiding alkalinizing foods and medications.
No, methenamine hippurate is classified as a urinary antiseptic, not an antibiotic. Unlike antibiotics, bacteria do not develop resistance to methenamine because its active metabolite (formaldehyde) works through a non-specific mechanism that denatures bacterial proteins. This makes it particularly valuable for long-term UTI prophylaxis without contributing to the global problem of antimicrobial resistance.
The duration of treatment depends on your individual clinical situation and should be determined by your healthcare provider. For prevention of recurrent UTIs, methenamine hippurate is typically prescribed for several months, and some patients may continue therapy for a year or longer. Your doctor will periodically reassess the need for continued treatment based on your UTI frequency and overall health.
References
All medical information in this article is based on peer-reviewed research, international guidelines, and evidence-based medicine principles. The following sources were used:
- Lee BSB, Bhuta T, Simpson JM, Craig JC. Methenamine hippurate for preventing urinary tract infections. Cochrane Database of Systematic Reviews. 2012;(10):CD003265. doi:10.1002/14651858.CD003265.pub3
- European Association of Urology (EAU). EAU Guidelines on Urological Infections. 2024 Edition. Available at: uroweb.org
- National Institute for Health and Care Excellence (NICE). Urinary tract infection (recurrent): antimicrobial prescribing. NICE Guideline [NG112]. 2018 (updated 2024).
- Harding GKM, Ronald AR. A controlled study of antimicrobial prophylaxis of recurrent urinary infection in women. New England Journal of Medicine. 1974;291(12):597-601.
- Flower A, Bishop FL, Lewith GT. Combination antimicrobials for treating urinary tract infections: a systematic review. Journal of Clinical Pharmacy and Therapeutics. 2014;39(3):218-231.
- World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023.
- British National Formulary (BNF). Methenamine hippurate. NICE/BNF. Accessed December 2025.
- Navarro-Llavat M, Domenech E, Bernal I, et al. Efficacy of methenamine hippurate in the prevention of recurrent bacteriuria: a systematic review and meta-analysis. BMC Urology. 2023;23:142.
- Carey M, Bower W, Rosamilia A, et al. ALTAR trial: a multicentre, pragmatic, randomised controlled trial of methenamine hippurate for recurrent UTI prevention. BMJ. 2022;376:e068825.
- Forbes R, Ali A, Abouhajar A, et al. Methenamine hippurate compared with antibiotic prophylaxis to prevent recurrent urinary tract infections in women: the ALTAR non-inferiority RCT. Health Technology Assessment. 2022;26(23).
Editorial Team
This article has been written and medically reviewed by the iMedic Medical Editorial Team, which consists of licensed specialist physicians with expertise in clinical pharmacology, urology, and infectious diseases.
Written by qualified medical professionals following international pharmacological guidelines (EAU, NICE, WHO, BNF)
Independently reviewed by iMedic Medical Review Board for accuracy and completeness
Level 1A – Based on systematic reviews and meta-analyses of randomized controlled trials
No commercial funding or pharmaceutical company sponsorship. Fully independent editorial content